The combination of CJC-1295 and Ipamorelin represents one of the most commonly used growth hormone secretagogue protocols in clinical practice. Unlike direct growth hormone administration, these peptides stimulate the body’s own pulsatile release of growth hormone — a distinction that has both physiological and regulatory implications. Here is what the evidence supports, where it falls short, and how I approach these peptides when I help patients make an informed decision.
At a Glance
| Property | Detail |
|---|---|
| Type | CJC-1295: synthetic GHRH analog; Ipamorelin: synthetic GH secretagogue |
| Amino acid count | CJC-1295: 29; Ipamorelin: 5 |
| Primary mechanism | Stimulation of pulsatile GH release from the anterior pituitary |
| Evidence level | Small controlled human studies of each peptide (hormone levels only; CJC-1295 data are from the DAC version); no published trial of the combination |
| Regulatory status | Not FDA-approved; FDA-flagged compounding safety risk; not EMA/BfArM-authorised; WADA-prohibited |
| Route of administration | SC injection |
What Are CJC-1295 and Ipamorelin?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the anterior pituitary to release growth hormone. The “CJC” designation refers to the research group (ConjuChem) that developed it. The version most commonly used in clinical practice is Modified GRF 1-29 (also called CJC-1295 without DAC), which is the first 29 amino acids of GHRH with four amino acid substitutions that improve metabolic stability. For a clinical comparison of Modified GRF 1-29 (CJC-1295 without DAC) versus sermorelin — including how half-life and pulsatility differ between these two GHRH analogues — see Sermorelin vs CJC-1295: Which Growth Hormone Peptide Is Right for You?. The DAC (Drug Affinity Complex) version, which binds to albumin and extends the half-life to days, is less commonly used in clinical practice due to concerns about sustained non-pulsatile GH elevation.
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue receptor (GHSR) agonist. Unlike other GH secretagogues such as GHRP-2 and GHRP-6, Ipamorelin is notably selective — it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels. This selectivity is clinically relevant because it means Ipamorelin can enhance GH release without the side effects associated with cortisol and prolactin elevation. For a detailed standalone guide covering ipamorelin’s mechanism, GHRP comparisons, IGF-1 monitoring, and candidacy criteria, see Ipamorelin: A Physician’s Guide.
The Rationale for Combination
The combination of CJC-1295 and Ipamorelin is based on the physiological principle that GH release from the pituitary is regulated by two signals: GHRH (the “accelerator”) and ghrelin/GH secretagogues (acting through a different receptor, also promoting release). By stimulating both pathways simultaneously, the combination produces a more robust and physiological GH pulse than either peptide alone.
This dual-pathway approach also preserves the pulsatile nature of GH release — the body’s normal pattern of releasing GH in bursts, primarily during sleep. This is in contrast to exogenous GH injection, which delivers a bolus of GH that does not replicate the natural pulsatile pattern.
Mechanism of Action
Primary Pathways
- GHRH Receptor Activation (CJC-1295): CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and release of growth hormone. It also promotes GH gene transcription, which means it increases the pituitary’s capacity to produce GH over time — not just its immediate release.
- GHS Receptor Activation (Ipamorelin): Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by ghrelin. This provides a complementary stimulus for GH release through a distinct intracellular signaling pathway (primarily involving IP3/DAG and calcium signaling, as opposed to the cAMP pathway used by GHRH).
- IGF-1 Elevation: The downstream effect of increased GH secretion is elevation of insulin-like growth factor 1 (IGF-1), primarily produced by the liver in response to GH stimulation. IGF-1 is the principal mediator of GH’s anabolic effects on muscle, bone, and other tissues.
- Negative Feedback Preservation: Unlike exogenous GH, which can suppress the hypothalamic-pituitary axis, CJC-1295/Ipamorelin works within the body’s feedback system. Somatostatin, the GH-inhibiting hormone, still functions normally, preventing excessive GH elevation and maintaining physiological pulsatility.
Research Assessment
What the Evidence Shows
| Claimed Effect | Evidence Level | Key Studies | Assessment |
|---|---|---|---|
| GH and IGF-1 elevation (CJC-1295 with DAC) | Controlled human studies | Teichman 2006; Ionescu 2006 | Consistent, but short studies with hormone endpoints only |
| Body composition improvement | Clinical observation and community reports | None published for either peptide or the combination | Unproven |
| Improved sleep quality | Clinical observation | - | Preliminary |
| Enhanced recovery | Clinical observation | - | Preliminary |
| Selective GH release (Ipamorelin) | Animal studies (rat pituitary cells, rats, pigs) | Raun 1998 | Shown in animals; not measured in human studies |
CJC-1295 has been studied in human clinical trials. Teichman and colleagues (2006) showed that a single injection of the DAC version raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days, with a half-life of 5.8-8.1 days. A week after a single injection, GH pulses were still present, while trough GH rose 7.5-fold (Ionescu 2006). The modified GRF 1-29 version without DAC has no published human studies; the shorter, pulse-like GH response attributed to it is inferred from its short half-life, not measured.
Ipamorelin has been studied in both animal and human settings. The selectivity data come from animal pharmacology: in pigs, GHRP-2 and GHRP-6 raised ACTH and cortisol while ipamorelin did not, even at doses more than 200-fold above its GH-releasing dose, and none of the three changed prolactin (Raun 1998). In healthy men, intravenous ipamorelin produced a single GH pulse at every dose tested (Gobburu 1999); cortisol and prolactin were not the focus of that study.
What the Evidence Does Not Show
The combination of CJC-1295 and Ipamorelin has not been studied in a rigorous clinical trial for any specific clinical outcome. The body composition benefits, improved sleep quality, and enhanced recovery that are commonly attributed to this combination are based on clinical observation and physiological reasoning from the known effects of GH optimization.
The long-term safety of chronic GH secretagogue use has not been established. While the physiological pulsatile pattern is presumably safer than supraphysiological exogenous GH, this assumption has not been formally tested over multi-year durations.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Nightly GH support, combined | CJC-1295 (no DAC) 100-300 mcg + ipamorelin 100-300 mcg in one injection; 200 + 200 mcg is the commonest pairing | SC, 30-60 minutes before sleep, away from food | 5-6 nights a week | 8-16 weeks on, 4-8 weeks off | Practice protocol |
| ”Saturation dose” protocol | 100 mcg of each per injection | SC, fasted | 2-3 times daily | 8-16 weeks | Practice protocol |
| Ipamorelin in the combination, forum protocol | 200-300 mcg | SC | 2-3 times daily | 8-12 weeks on, 4-6 weeks off | Practice protocol |
| CJC-1295 with DAC, forum protocol | 1-2 mg per week | SC | 1-2 injections per week | 8-16 weeks on, 4-6 weeks off | Practice protocol |
| CJC-1295 with DAC, healthy adults | 30 or 60 mcg/kg (about 2.1-4.2 mg at 70 kg) | SC | Weekly or every 2 weeks, 2-3 doses | 28-49 days | Trial (Teichman 2006) |
Sources for each row are in the protocol table of the dosage guide. Note: These peptides are typically administered together as a single injection before bedtime to coincide with the natural nocturnal GH surge. Dosing is based on clinical practice, not formal dose-finding studies for the combination. Cycling (8-16 weeks on, 4-8 weeks off) is commonly recommended to prevent pituitary desensitization, though the necessity of cycling has not been established in clinical trials. Patients who are unwilling or unable to self-inject may consider ibutamoren (MK-677) — an oral ghrelin receptor agonist that achieves similar GH pulse amplification through a non-peptide mechanism, with the trade-off of greater appetite stimulation and a more pronounced effect on insulin sensitivity. For the published human dose data, see CJC-1295/Ipamorelin Dosage.
Neither peptide has an approved dose. The FDA has flagged both as compounding substances that may present significant safety risks, noting serious adverse events with CJC-1295 (increased heart rate, a systemic vasodilatory reaction) and with ipamorelin, including a death when it was given intravenously.
What People Report: What Works and What Doesn’t
Sources: the aggregated community data sets for CJC-1295 without DAC (180 reports) and ipamorelin (200 reports), the side-effect lists on Peptide DB, and a 2026 peer-reviewed review that sets forum protocols against the clinical evidence (Dominikowski 2026). Doses and their sources are in the protocol table.
Reported to work
- Deeper sleep and more vivid dreams within the first 1-2 weeks, the earliest and most consistent report.
- Better recovery from training and less soreness after 2-4 weeks.
- Gradual changes in body composition, more lean mass and less fat, over 2-4 months.
- Skin that looks and feels better over several months.
Mixed or unclear
- Body composition. It is the main reason people use the combination, yet the review finds no peer-reviewed support for meaningful effects on body composition or performance from CJC-1295 without DAC, which has no published human studies.
- IGF-1. People who test often see it rise, which fits the DAC trials, but a higher IGF-1 is a marker, not an outcome.
- Once nightly versus two or three times a day. Both have followers; no comparison exists.
- Whether cycling prevents loss of effect. Widely practised, never tested.
Reported not to work, or disappointing
- Tingling or numbness in the hands and feet shortly after injection, which the community reads as a sign of GH release; persistent numbness is a warning sign.
- Flushing and warmth for 5-10 minutes after an injection, headache, tiredness, and water retention; the review lists fluid retention, paraesthesia and joint pain among the signals of raising GH.
- Changes in blood sugar: the review lists dysglycaemia as a class signal and recommends checking fasting glucose or HbA1c in users.
- Serious reactions are rare but documented: the FDA has recorded a fast heart rate and a systemic vasodilatory reaction with CJC-1295.
What a properly designed trial would need to show: a placebo-controlled trial of the nightly combination at 100-300 mcg each for 16-24 weeks in middle-aged adults, with DEXA body composition, strength, sleep measures, IGF-1, glucose and HbA1c, and a follow-up after stopping.
Safety and Side Effects
Known
Common side effects include injection site reactions, water retention (particularly in the first 1-2 weeks), transient numbness or tingling in the extremities (a recognized effect of GH elevation), and increased appetite (more common with Ipamorelin). These effects are generally mild and dose-dependent.
Theoretical Concerns
The oncological implications of sustained GH/IGF-1 elevation deserve attention. IGF-1 is a growth factor that promotes cell proliferation, and epidemiological data links chronically elevated IGF-1 levels to increased cancer risk. The question is whether the modest, pulsatile GH elevation produced by secretagogues carries the same risk as chronically elevated levels. This question remains unanswered.
Insulin sensitivity may be affected by GH secretagogues. GH is a counter-regulatory hormone that opposes insulin action. Sustained GH elevation can worsen insulin resistance, which is particularly relevant in patients with pre-diabetes or metabolic syndrome.
Contraindications
Active malignancy. Diabetes or significant insulin resistance (relative contraindication — requires careful monitoring). Pituitary disorders. Pregnancy and lactation. Children (risk of premature growth plate closure).
Drug and Supplement Interactions
GH secretagogues should be used with caution alongside insulin or oral hypoglycemic agents due to the counter-regulatory effects of GH on glucose metabolism. Concurrent use with exogenous GH is contraindicated due to risk of supraphysiological GH levels. Glucocorticoids may blunt the GH-releasing effects of these peptides.
Clinical Perspective
CJC-1295/Ipamorelin is a peptide combination that I approach with measured enthusiasm. The pharmacology is sound — stimulating pulsatile, physiological GH release through two complementary pathways is more elegant than direct GH injection. And the selectivity of Ipamorelin, in particular, addresses many of the side effect concerns associated with older GH secretagogues.
The people most likely to benefit from GH secretagogues are those with documented evidence of GH insufficiency — typically adults over 40 with low IGF-1 levels who present with symptoms consistent with GH decline: increased adiposity (particularly visceral), reduced lean mass, poor recovery from exercise or injury, and diminished sleep quality. Confirmed adult GH deficiency also has approved treatments, which belong in the discussion. Where visceral adiposity is a primary concern alongside confirmed GH insufficiency, AOD 9604 is sometimes layered in — the hGH C-terminal fragment that stimulates lipolysis directly through the β3-adrenergic pathway without raising IGF-1. The mechanisms are entirely distinct, although the combination itself has not been tested in a human trial.
When patients ask me about CJC-1295/ipamorelin, I explain that GH secretagogues are not anabolic steroids. The GH elevation produced by CJC-1295/Ipamorelin is within the physiological range. Any improvements in body composition, recovery, and sleep quality should be expected to be gradual, over 8-12 weeks — not dramatic overnight changes. Realistic expectations matter.
IGF-1 levels, fasting glucose, and insulin should be monitored at baseline and during treatment by the treating physician. If IGF-1 exceeds the upper end of the age-appropriate reference range, or if glucose homeostasis deteriorates, the protocol should be adjusted or stopped. This is not a set-and-forget intervention.
The regulatory landscape has changed significantly. In the United States the FDA lists CJC-1295 and ipamorelin among compounding substances that may present significant safety risks, neither is authorised by the EMA or BfArM, and both are prohibited by WADA. In jurisdictions where they remain available through medical channels, they can be a useful tool for appropriate candidates — always within the context of comprehensive metabolic assessment and monitoring.
References
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683
- Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID 17018654
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822
- Gobburu JV, et al. “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharm Res. 1999;16(9):1412-1416. PMID 10496658
- Nass R, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PMID 18981485
- Veldhuis JD, et al. “Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay.” J Clin Endocrinol Metab. 1995;80(11):3209-3222. PMID 7593428
Disclaimer: This peptide profile is intended for educational purposes. CJC-1295 and Ipamorelin are not FDA-approved and have been restricted from US compounding. Availability varies by jurisdiction. Consult a qualified physician before pursuing any peptide therapy.
